Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura C Cappelli

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
RMD Open|November 1, 2023
Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseasesPaola Ghanem, Joseph C Murray, Kristen A Marrone, et al.
Journal for Immunotherapy of Cancer|March 31, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminologyJarushka Naidoo, Catherine Murphy, Michael B Atkins, et al.
ACR Open Rheumatology|February 11, 2021
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis RegistryJoel M Kremer, Clifton O Bingham, Laura C Cappelli, et al.
Rheumatology Advances in Practice|June 7, 2022
Experience with telemedicine among rheumatology clinicians during the COVID-19 pandemic: an international surveyEugenia Yupei Chock, Michael Putman, Richard Conway, et al.
Annals of the Rheumatic Diseases|April 12, 2026
Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry studyDeanna P Jannat-Khah, Pankti Reid, Laura C Cappelli, et al.
Journal for Immunotherapy of Cancer|May 28, 2026
Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort studyAlice Tison, Deanna Jannat-Khah, Laura C Cappelli, et al.
The Journal of Investigative Dermatology|May 23, 2022
Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance StudyThomas K Le, Isabelle Brown, Rebecca Goldberg, et al.
Journal of Translational Medicine|March 5, 2024
Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockadeShuming Chen, Tracee L McMiller, Abha Soni, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse EventsJarushka Naidoo, Jiajia Zhang, Evan J Lipson, et al.
The Oncologist|July 27, 2024
Immune-related encephalitis after immune checkpoint inhibitor therapyMonica W Buckley, Aanika Balaji Warner, Julie Brahmer, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
RMD Open|November 1, 2023
Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseasesPaola Ghanem, Joseph C Murray, Kristen A Marrone, et al.
Journal for Immunotherapy of Cancer|March 31, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminologyJarushka Naidoo, Catherine Murphy, Michael B Atkins, et al.
ACR Open Rheumatology|February 11, 2021
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis RegistryJoel M Kremer, Clifton O Bingham, Laura C Cappelli, et al.
Rheumatology Advances in Practice|June 7, 2022
Experience with telemedicine among rheumatology clinicians during the COVID-19 pandemic: an international surveyEugenia Yupei Chock, Michael Putman, Richard Conway, et al.
Annals of the Rheumatic Diseases|April 12, 2026
Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry studyDeanna P Jannat-Khah, Pankti Reid, Laura C Cappelli, et al.
Journal for Immunotherapy of Cancer|May 28, 2026
Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort studyAlice Tison, Deanna Jannat-Khah, Laura C Cappelli, et al.
The Journal of Investigative Dermatology|May 23, 2022
Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance StudyThomas K Le, Isabelle Brown, Rebecca Goldberg, et al.
Journal of Translational Medicine|March 5, 2024
Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockadeShuming Chen, Tracee L McMiller, Abha Soni, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse EventsJarushka Naidoo, Jiajia Zhang, Evan J Lipson, et al.
The Oncologist|July 27, 2024
Immune-related encephalitis after immune checkpoint inhibitor therapyMonica W Buckley, Aanika Balaji Warner, Julie Brahmer, et al.
Pageof 6